European cardiology最新文献_第4页

Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review. 左西孟旦--治疗心源性休克的前景看好的药物疗法：全面综述。

European cardiology Pub Date : 2024-11-12 eCollection Date: 2024-01-01 DOI: 10.15420/ecr.2024.16

Hendri Susilo, Fan Maitri Aldian, Citrawati Dyah Kencono Wungu, Mochamad Yusuf Alsagaff, Henry Sutanto, Chaq El Chaq Zamzam Multazam

{"title":"Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review.","authors":"Hendri Susilo, Fan Maitri Aldian, Citrawati Dyah Kencono Wungu, Mochamad Yusuf Alsagaff, Henry Sutanto, Chaq El Chaq Zamzam Multazam","doi":"10.15420/ecr.2024.16","DOIUrl":"10.15420/ecr.2024.16","url":null,"abstract":"Cardiogenic shock (CS) is a critical condition with high mortality rate, as the current management of CS presents significant challenges. Exploration of more effective therapies is necessitated. This review article comprehensively examines the efficacy and safety of levosimendan in the management of CS. By synthesising evidence from numerous studies, a comparison of levosimendan over traditional inotropic agents, such as enoximone, dobutamine, dopamine and norepinephrine, is highlighted. The unique mechanism of action of levosimendan enhances myocardial contractility without increasing oxygen demand, offering a promising alternative for patients with CS. This review also delves into comparative studies that demonstrate the superiority of levosimendan in improving survival rates, haemodynamic parameters, and reducing the incidence of CS complications. Safety profiles and adverse effects are critically assessed to provide a balanced view of the therapeutic window provided by levosimendan. The review concludes that levosimendan is a valuable addition to the therapeutic strategy against CS, with the potential to improve patient outcomes.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"19 ","pages":"e21"},"PeriodicalIF":0.0,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142718106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic Yield of Comprehensive Coronary Function Testing in Patients with Angina and Unobstructed Coronary Arteries: Endotype Characterisation and Clinical Implications. 心绞痛和冠状动脉通畅患者的综合冠状动脉功能测试诊断率：内型特征和临床意义。

European cardiology Pub Date : 2024-11-11 eCollection Date: 2024-01-01 DOI: 10.15420/ecr.2024.32

Johanna McChord, Astrid Hubert, Udo Sechtem, Raffi Bekeredjian, Peter Ong, Andreas Seitz

{"title":"Diagnostic Yield of Comprehensive Coronary Function Testing in Patients with Angina and Unobstructed Coronary Arteries: Endotype Characterisation and Clinical Implications.","authors":"Johanna McChord, Astrid Hubert, Udo Sechtem, Raffi Bekeredjian, Peter Ong, Andreas Seitz","doi":"10.15420/ecr.2024.32","DOIUrl":"10.15420/ecr.2024.32","url":null,"abstract":"Background: Coronary functional disorders (CFD) are significant contributors to angina with non-obstructed coronary arteries (ANOCA). Various endotypes, such as epicardial or microvascular spasm and/or coronary microvascular dysfunction (CMD), have been identified. Previous studies have shown a high prevalence of CFD in ANOCA cases, but often lacked comprehensive coronary functional testing (CFT), which ideally includes coronary spasm provocation testing and CMD assessment. This study aims to investigate the prevalence of CFD and to characterise endotypes in ANOCA patients using comprehensive CFT.Methods: A total of 89 consecutive ANOCA patients (mean age 64, 69% women) who underwent comprehensive CFT were enrolled. CFT comprised acetylcholine (ACh) spasm provocation testing and assessment of coronary flow reserve (CFR) and hyperaemic microvascular resistance using Doppler technique.Results: CFT identified at least one coronary vasomotion disorder in 91% of patients with ANOCA. Among them, microvascular spasm was the most common endotype (61%), followed by CMD (43%). Only 9% of patients had isolated CMD with the remaining CMD patients also showing coronary spasm. Low CFR was mainly associated with high resting coronary flow rather than impaired hyperaemic flow (R -0.60, p<0.0001). Additionally, 48% of patients with microvascular spasm exhibited moderate to severe coronary tortuosity.Conclusion: CFT provides a high diagnostic yield of CFD in ANOCA patients. Coronary spasm, particularly microvascular spasm, is the most frequent endotype. Patients with isolated CMD are rare, highlighting the importance of spasm testing in the ANOCA population.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"19 ","pages":"e19"},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142718053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Staging Heart Failure with Preserved Ejection Fraction by Assessing Cardiac Chamber Involvement. 通过评估心腔受累情况对射血分数保留型心力衰竭进行分期

European cardiology Pub Date : 2024-11-11 eCollection Date: 2024-01-01 DOI: 10.15420/ecr.2024.31

Anastasia Shchendrygina, Ilya Giverts, Mariya Tokmakova, Ekaterina Kharchenko, Alisa Vlasova, Anastasia Rogova, Nikita Zakharov, Nadezda Mukhina

引用次数: 0

Sex Difference in 5-year Relative Survival Following Percutaneous Coronary Intervention. 经皮冠状动脉介入治疗后 5 年相对存活率的性别差异。

European cardiology Pub Date : 2024-10-02 eCollection Date: 2024-01-01 DOI: 10.15420/ecr.2024.25

Jin-Ho Choi, Jung-Min Choi, Ki-Hong Choi, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Eun-Seok Shin

{"title":"Sex Difference in 5-year Relative Survival Following Percutaneous Coronary Intervention.","authors":"Jin-Ho Choi, Jung-Min Choi, Ki-Hong Choi, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Eun-Seok Shin","doi":"10.15420/ecr.2024.25","DOIUrl":"https://doi.org/10.15420/ecr.2024.25","url":null,"abstract":"Background: Survival rates following percutaneous coronary intervention (PCI) show variability across studies, particularly regarding sex-specific outcomes. Relative survival analysis, which considers survival patterns in sex-and age-matched general populations, could help explain this variability.Methods: In a 2011 nationwide South Korean PCI cohort study with 48,783 patients, all-cause death was assessed as the primary outcome over 5 years. Observed and relative survival rates at 5 years conditional on surviving 0 days, 30 days, 1 year, and 2 years were assessed. Sex-specific differences in clinical characteristics were adjusted using propensity score-matching.Results: In the unadjusted analyses, 15,710 females had more cardiovascular risk factors than 33,073 males. Both observed survival (HR 1.28; 95% CI [1.22-1.34]) and relative survival (HR 1.21; 95% CI [1.16-1.27]) were lower in females than males (all p<0.001). In the analyses of 14,454 matched pairs, females showed higher observed survival (HR 0.78; 95% CI [0.74-0.82]), but lower relative survival (HR 1.19; 95% CI [1.13-1.26]), compared to males (all p<0.001). This trend was particularly notable in females aged 60 years or older. These findings persisted in analyses conditional on surviving 30 days, 1 year and 2 years.Conclusion: The adjusted 5-year relative survival of older females was lower than that of age-matched males, highlighting the need for the excessive risk reduction in older females undergoing PCI.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"19 ","pages":"e18"},"PeriodicalIF":0.0,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Need for Separate Testing with Acetylcholine for the Assessment of Endothelial Dysfunction and Coronary Artery Spasm. 用乙酰胆碱分别测试评估内皮功能障碍和冠状动脉痉挛的必要性。

European cardiology Pub Date : 2024-09-19 eCollection Date: 2024-01-01 DOI: 10.15420/ecr.2022.16

Shozo Sueda, Tomoki Sakaue

引用次数: 0

A Review of the Role of Tests of Coronary Reactivity in Clinical Practice. 冠状动脉反应性测试在临床实践中的作用回顾。

European cardiology Pub Date : 2024-08-21 eCollection Date: 2024-01-01 DOI: 10.15420/ecr.2022.12

Shozo Sueda, Tomoki Sakaue

引用次数: 0

Corrigendum: Assessment of the Ischaemic Effects of Myocardial Bridge by Echocardiographic Exercise Stress Test. 更正：通过超声心动图运动负荷试验评估心肌桥的缺血性效应。

European cardiology Pub Date : 2024-08-09 eCollection Date: 2024-01-01 DOI: 10.15420/ecr.2024.co1

Priscilla Lamendola, Nello Cambise, Antonio Di Renzo, Lorenzo Tinti, Antonio De Vita, Saverio Tremamunno, Paola Pastena, Antonietta Belmusto, Rocco Antonio Montone, Riccardo Rinaldi, Angelo Villano, Gaetano A Lanza

引用次数: 0

Unusual Presentations of Thyrotoxic Tricuspid and Mitral Regurgitations in 62 Adults: A Systematic Review of Case Reports with In-depth Pathophysiological Review. 62 名成人甲亢三尖瓣和二尖瓣反流的异常表现：病例报告的系统回顾与深入病理生理学回顾。

European cardiology Pub Date : 2024-07-29 eCollection Date: 2024-01-01 DOI: 10.15420/ecr.2024.05

Andro Pramana Witarto, Bendix Samarta Witarto, Shidi Laras Pramudito, Lintang Cahyaning Ratri, Della Anastasia Candra, Stephanie Wirakasa, Hermina Novida, Hendri Susilo, Citrawati Dyah Kencono Wungu, Maya Kusumawati

{"title":"Unusual Presentations of Thyrotoxic Tricuspid and Mitral Regurgitations in 62 Adults: A Systematic Review of Case Reports with In-depth Pathophysiological Review.","authors":"Andro Pramana Witarto, Bendix Samarta Witarto, Shidi Laras Pramudito, Lintang Cahyaning Ratri, Della Anastasia Candra, Stephanie Wirakasa, Hermina Novida, Hendri Susilo, Citrawati Dyah Kencono Wungu, Maya Kusumawati","doi":"10.15420/ecr.2024.05","DOIUrl":"10.15420/ecr.2024.05","url":null,"abstract":"Background: Thyrotoxicosis is related to cardiovascular mortality. This can be caused by several clinical manifestations involving the rare provocation of tricuspid regurgitation (TR) and mitral regurgitation (MR). However, there are still no clear data on thyrotoxic TR and/or MR. This study examines the progression of TR, MR, heart failure (HF) and pulmonary hypertension (PH) in response to the thyrotoxic heart manifestations, clinical characteristics and treatment approaches.Methods: A PRISMA-based systematic search was conducted using PubMed and other databases up to 17 June 2023. The outcomes of this study were TR, MR, HF and PH with their progression on follow-up, clinical characteristics and treatment approaches.Results: A total of 57 case reports involving 62 patients (45.77 ± 13.41 years) were included in this study. They were predominantly women (n=50; 80.65%) and diagnosed with Graves' disease (n=41; 75.81%). All patients were diagnosed with thyrotoxicosis, and this included 23 (37.10%) cases of thyroid storm. From echocardiographic studies, several patients improved clinically within the first 6 months of follow-up, including 20 TR patients (83.33%) in 6 months, nine MR patients (69.23%) in 3 months, eight HF patients (66.67%) in 2 months and 16 PH patients (76.19%) in 6 months.Conclusion: Several mechanisms are involved in thyrotoxic TR and/or MR, including the direct thyroid hormone effect and the indirect effect of other hyperthyroidism-associated factors. Patients with thyrotoxic TR and/or MR, including those with HF and PH, can experience clinical and structural improvements following hyperthyroidism treatment in the first 6 months.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"19 ","pages":"e13"},"PeriodicalIF":0.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11322951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment Options and Continuity of Care in Metabolic-associated Fatty Liver Disease: A Multidisciplinary Approach. 代谢相关性脂肪肝的治疗方案和持续护理：多学科方法。

European cardiology Pub Date : 2024-06-19 eCollection Date: 2024-01-01 DOI: 10.15420/ecr.2023.34

Carmen Lara-Romero, Manuel Romero-Gómez

{"title":"Treatment Options and Continuity of Care in Metabolic-associated Fatty Liver Disease: A Multidisciplinary Approach.","authors":"Carmen Lara-Romero, Manuel Romero-Gómez","doi":"10.15420/ecr.2023.34","DOIUrl":"10.15420/ecr.2023.34","url":null,"abstract":"The terms non-alcoholic fatty liver disease and non-alcoholic steatohepatitis have some limitations as they use exclusionary confounder terms and the use of potentially stigmatising language. Recently, a study with content experts and patients has been set to change this nomenclature. The term chosen to replace non-alcoholic fatty liver disease was metabolic dysfunction-associated steatotic liver disease (MASLD), which avoids stigmatising and helps improve awareness and patient identification. MASLD is the most common cause of chronic liver disease with an increasing prevalence, accounting for 25% of the global population. It is considered the hepatic manifestation of the metabolic syndrome with lifestyle playing a fundamental role in its physiopathology. Diet change and physical activity are the cornerstones of treatment, encompassing weight loss and healthier behaviours and a holistic approach. In Europe, there is no approved drug for MASLD to date and there is a substantial unmet medical need for effective treatments for patients with MASLD. This review not only provides an update on advances in evidence for nutrition and physical activity interventions but also explores the different therapeutic options that are being investigated and whose development focuses on the restitution of metabolic derangements and halting inflammatory and fibrogenic pathways.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"19 ","pages":"e06"},"PeriodicalIF":0.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141565576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Maternal Cardiac Function in Pregnancies with Metabolic Disorders. 代谢紊乱孕妇的母体心脏功能

European cardiology Pub Date : 2024-06-19 eCollection Date: 2024-01-01 DOI: 10.15420/ecr.2023.28

Deesha Patel, Makrina D Savvidou

引用次数: 0